Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): A new mediator involved in early ankylosing spondylitis

Chun Hsiung Chen, Hsien Tzung Liao, Hung An Chen, Toong Hua Liang, Chin Tien Wang, Chung Tei Chou

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective. To investigate the possible role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in ankylosing spondylitis (AS). Methods. Serum sTREM-1 levels were measured in 80 patients withAS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patients using ELISA. Demographic data were collected, and patient's disease activity (BASDAI), functional ability (BASFI), and global assessment (BAS-G) were evaluated. We also tested erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgA in these patients. Results. Serum sTREM-1 levels were detectable (definition, ≥ 15 pg/ml) in 31.3% (25/80) of the AS patients, as compared to only 10% (3/30) of healthy controls (p = 0.027). SF sTREM-1 levels were detectable (≥ 15 pg/ml) in 83% (5/6) of the AS patients. The detectable rate of sTREM-1 in SF was significantly higher than in serum (p = 0.018). Disease duration was shorter in AS patients with "higher" serum sTREM-1 levels (≥ 30 pg/ml) versus those with "lower" levels (<30 pg/ml) [mean (SD), 4.3 (3.7) vs 8.6 (7.8) yrs, p = 0.036], but the differences between these 2 groups of patients were not evident based on results of BASDAI, BASFI, BAS-G, ESR, CRP, or IgA levels. Of note, serum sTREM-1 levels inversely correlated with disease duration (r = -0.433, p = 0.03) in the 25 AS patients with detectable sTREM-1 levels. Conclusion. sTREM-1 seems to be a new mediator involved in patients with AS, particularly in the early stages of disease. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)1846-1848
Number of pages3
JournalJournal of Rheumatology
Volume35
Issue number9
Publication statusPublished - Sep 2008

Fingerprint

Ankylosing Spondylitis
Myeloid Cells
Synovial Fluid
Serum
Blood Sedimentation
C-Reactive Protein
Immunoglobulin A
Rheumatology
Enzyme-Linked Immunosorbent Assay
Demography

Keywords

  • Ankylosing spondylitis
  • Disease duration
  • Serum
  • Soluble triggering receptor expressed on myeloid cell-1
  • Synovial fluid

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Chen, C. H., Liao, H. T., Chen, H. A., Liang, T. H., Wang, C. T., & Chou, C. T. (2008). Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): A new mediator involved in early ankylosing spondylitis. Journal of Rheumatology, 35(9), 1846-1848.

Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1) : A new mediator involved in early ankylosing spondylitis. / Chen, Chun Hsiung; Liao, Hsien Tzung; Chen, Hung An; Liang, Toong Hua; Wang, Chin Tien; Chou, Chung Tei.

In: Journal of Rheumatology, Vol. 35, No. 9, 09.2008, p. 1846-1848.

Research output: Contribution to journalArticle

Chen, CH, Liao, HT, Chen, HA, Liang, TH, Wang, CT & Chou, CT 2008, 'Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): A new mediator involved in early ankylosing spondylitis', Journal of Rheumatology, vol. 35, no. 9, pp. 1846-1848.
Chen, Chun Hsiung ; Liao, Hsien Tzung ; Chen, Hung An ; Liang, Toong Hua ; Wang, Chin Tien ; Chou, Chung Tei. / Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1) : A new mediator involved in early ankylosing spondylitis. In: Journal of Rheumatology. 2008 ; Vol. 35, No. 9. pp. 1846-1848.
@article{995fca36f283450c9224731a12fd06fd,
title = "Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): A new mediator involved in early ankylosing spondylitis",
abstract = "Objective. To investigate the possible role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in ankylosing spondylitis (AS). Methods. Serum sTREM-1 levels were measured in 80 patients withAS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patients using ELISA. Demographic data were collected, and patient's disease activity (BASDAI), functional ability (BASFI), and global assessment (BAS-G) were evaluated. We also tested erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgA in these patients. Results. Serum sTREM-1 levels were detectable (definition, ≥ 15 pg/ml) in 31.3{\%} (25/80) of the AS patients, as compared to only 10{\%} (3/30) of healthy controls (p = 0.027). SF sTREM-1 levels were detectable (≥ 15 pg/ml) in 83{\%} (5/6) of the AS patients. The detectable rate of sTREM-1 in SF was significantly higher than in serum (p = 0.018). Disease duration was shorter in AS patients with {"}higher{"} serum sTREM-1 levels (≥ 30 pg/ml) versus those with {"}lower{"} levels (<30 pg/ml) [mean (SD), 4.3 (3.7) vs 8.6 (7.8) yrs, p = 0.036], but the differences between these 2 groups of patients were not evident based on results of BASDAI, BASFI, BAS-G, ESR, CRP, or IgA levels. Of note, serum sTREM-1 levels inversely correlated with disease duration (r = -0.433, p = 0.03) in the 25 AS patients with detectable sTREM-1 levels. Conclusion. sTREM-1 seems to be a new mediator involved in patients with AS, particularly in the early stages of disease. The Journal of Rheumatology",
keywords = "Ankylosing spondylitis, Disease duration, Serum, Soluble triggering receptor expressed on myeloid cell-1, Synovial fluid",
author = "Chen, {Chun Hsiung} and Liao, {Hsien Tzung} and Chen, {Hung An} and Liang, {Toong Hua} and Wang, {Chin Tien} and Chou, {Chung Tei}",
year = "2008",
month = "9",
language = "English",
volume = "35",
pages = "1846--1848",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "9",

}

TY - JOUR

T1 - Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1)

T2 - A new mediator involved in early ankylosing spondylitis

AU - Chen, Chun Hsiung

AU - Liao, Hsien Tzung

AU - Chen, Hung An

AU - Liang, Toong Hua

AU - Wang, Chin Tien

AU - Chou, Chung Tei

PY - 2008/9

Y1 - 2008/9

N2 - Objective. To investigate the possible role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in ankylosing spondylitis (AS). Methods. Serum sTREM-1 levels were measured in 80 patients withAS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patients using ELISA. Demographic data were collected, and patient's disease activity (BASDAI), functional ability (BASFI), and global assessment (BAS-G) were evaluated. We also tested erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgA in these patients. Results. Serum sTREM-1 levels were detectable (definition, ≥ 15 pg/ml) in 31.3% (25/80) of the AS patients, as compared to only 10% (3/30) of healthy controls (p = 0.027). SF sTREM-1 levels were detectable (≥ 15 pg/ml) in 83% (5/6) of the AS patients. The detectable rate of sTREM-1 in SF was significantly higher than in serum (p = 0.018). Disease duration was shorter in AS patients with "higher" serum sTREM-1 levels (≥ 30 pg/ml) versus those with "lower" levels (<30 pg/ml) [mean (SD), 4.3 (3.7) vs 8.6 (7.8) yrs, p = 0.036], but the differences between these 2 groups of patients were not evident based on results of BASDAI, BASFI, BAS-G, ESR, CRP, or IgA levels. Of note, serum sTREM-1 levels inversely correlated with disease duration (r = -0.433, p = 0.03) in the 25 AS patients with detectable sTREM-1 levels. Conclusion. sTREM-1 seems to be a new mediator involved in patients with AS, particularly in the early stages of disease. The Journal of Rheumatology

AB - Objective. To investigate the possible role of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in ankylosing spondylitis (AS). Methods. Serum sTREM-1 levels were measured in 80 patients withAS and 30 healthy controls, and synovial fluid (SF) sTREM-1 levels were tested in 6 AS patients using ELISA. Demographic data were collected, and patient's disease activity (BASDAI), functional ability (BASFI), and global assessment (BAS-G) were evaluated. We also tested erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and IgA in these patients. Results. Serum sTREM-1 levels were detectable (definition, ≥ 15 pg/ml) in 31.3% (25/80) of the AS patients, as compared to only 10% (3/30) of healthy controls (p = 0.027). SF sTREM-1 levels were detectable (≥ 15 pg/ml) in 83% (5/6) of the AS patients. The detectable rate of sTREM-1 in SF was significantly higher than in serum (p = 0.018). Disease duration was shorter in AS patients with "higher" serum sTREM-1 levels (≥ 30 pg/ml) versus those with "lower" levels (<30 pg/ml) [mean (SD), 4.3 (3.7) vs 8.6 (7.8) yrs, p = 0.036], but the differences between these 2 groups of patients were not evident based on results of BASDAI, BASFI, BAS-G, ESR, CRP, or IgA levels. Of note, serum sTREM-1 levels inversely correlated with disease duration (r = -0.433, p = 0.03) in the 25 AS patients with detectable sTREM-1 levels. Conclusion. sTREM-1 seems to be a new mediator involved in patients with AS, particularly in the early stages of disease. The Journal of Rheumatology

KW - Ankylosing spondylitis

KW - Disease duration

KW - Serum

KW - Soluble triggering receptor expressed on myeloid cell-1

KW - Synovial fluid

UR - http://www.scopus.com/inward/record.url?scp=54049158163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049158163&partnerID=8YFLogxK

M3 - Article

C2 - 18634145

AN - SCOPUS:54049158163

VL - 35

SP - 1846

EP - 1848

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 9

ER -